Abstract:Ferroptosis is a recently recognized form of regulated cell death, characterized by iron-dependent accumulation of lipid peroxidation. Ample evidence has depicted that ferroptosis plays an essential role in the cause or consequence of human diseases, including cancer, neurodegenerative disease and acute kidney injury. However, the exact role and underlying mechanism of ferroptosis in fibrotic kidney remain unknown. Acyl-CoA synthetase long-chain family member 4 (ACSL4) has been demonstrated as an essential component in ferroptosis execution by shaping lipid composition. In this study, we aim to discuss the potential role and underlying mechanism of ACSL4-mediated ferroptosis of tubular epithelial cells (TECs) during renal fibrosis. The unbiased gene expression studies showed that ACSL4 expression was tightly associated with decreased renal function and the progression of renal fibrosis. To explore the role of ACSL4 in fibrotic kidney, ACSL4 specific inhibitor rosiglitazone (ROSI) was used to disturb the high expression of ACSL4 in TECs induced by TGF-β, unilateral ureteral obstruction (UUO) and fatty acid (FA)-modeled mice in vivo, and ACSL4 siRNA was used to knockdown ACSL4 in TGF-β-induced HK2 cells in vitro. The results demonstrated that inhibition and knockdown of ACSL4 effectively attenuated the occurrence of ferroptosis in TECs and alleviated the interstitial fibrotic response. In addition, the expression of various profibrotic cytokines all decreased after ROSI-treated in vivo and in vitro. Further investigation showed that inhibition of ACSL4 obviously attenuates the progression of renal fibrosis by reducing the proferroptotic precursors arachidonic acid- and adrenic acid- containing phosphatidylethanolamine (AA-PE and AdA-PE). In conclusion, these results suggest ACSL4 is essential for tubular ferroptotic death during kidney fibrosis development and ACSL4 inhibition is a viable therapeutic approach to preventing fibrotic kidney diseases.

Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases

ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury

Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism

ACSL4-Mediated Ferroptosis and Its Potential Role in Central Nervous System Diseases and Injuries

Design, synthesis, and biological evaluation of 2-amino-6-methyl-phenol derivatives targeting lipid peroxidation with potent anti-ferroptotic activities

Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition

L-F001, a Multifunctional Fasudil-Lipoic Acid Dimer Prevents RSL3-Induced Ferroptosis Via Maintaining Iron Homeostasis and Inhibiting JNK in HT22 Cells.

Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease

Identification of Isoliensinine as a Ferroptosis Suppressor with Iron-Chelating Activity

Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species

Identification of Marine-Derived SLC7A11 Inhibitors: Molecular Docking, Structure-Based Virtual Screening, Cytotoxicity Prediction, and Molecular Dynamics Simulation

Astragaloside IV Inhibits Bleomycin-Induced Ferroptosis in Human Umbilical Vein Endothelial Cells by Mediating LPC

Identification of lipid senolytics targeting senescent cells through ferroptosis induction

Synthesis and Evaluation of Smart Drugs with Integrated Functions for Identifying and Treating Oxidative Microenvironments Associated with Cellular Ferroptosis

A new ferroptosis inhibitor, isolated from<i> Ajuga</i><i> nipponensis,</i> protects neuronal cells via activating NRF2-antioxidant response elements (AREs) pathway

The suppression of hyperlipid diet-induced ferroptosis of vascular smooth muscle cells protests against atherosclerosis independent of p53/SCL7A11/GPX4 axis

Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion

Non-classical Ferroptosis Inhibition by a Small Molecule Targeting PHB2

The Role of Ferroptosis in Amyotrophic Lateral Sclerosis Treatment